Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Risankizumab in Adult Japanese Subjects With Moderate to Severe Palmoplantar Pustulosis

NCT04451720 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04451720
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04451720 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Risankizumab in Adult Japanese Subjects With Moderate to Severe Palmoplantar Pustulosis
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Completed
Start date
July 20, 2020
Completion date
November 21, 2022
Enrollment
119 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

palmoplantar pustulosis (ppp)